The first patient expert training course of the European Patients' Academy (EUPATI) has begun.
The first patient expert training course of the European Patients’ Academy (EUPATI) has begun. The 15-month program is designed to meet the needs of patients and patient representatives and to impart expert knowledge about the whole spectrum of the medicine research and development process.
“The course is specifically designed to meet the needs of participants who are motivated with the skill set to acquire and apply this expert-level knowledge,” said Jan Geissler, EUPATI Director, who noted that earlier this month a webinar marked the official opening of the course and the launch of the online learning program for 53 participants.
The course comprises a mixture of online and face-to-face training and covers discovery, development, evaluation, marketing authorization and post-marketing evaluation, and other important subjects. Participants will take six e-learning modules covering a broad range of topics. They will also attend two face-to-face training events for interactive teaching and have the opportunity to meet directly with other patient experts and with specialists working in the field of medicine development.
The organizers plan to encourage participants to apply knowledge and skills acquired through three main areas:
The second wave of the program will start in September 2015. By 2016, there will be over 100 expert patients who will be able to share their expertise and help to reach the patient community, raise public awareness and generate dialogue around future patient involvement in research and development.
EUPATI received more than 300 applications for the course. An independent evaluation panel selected 53 participants based upon careful examination of all eligible applications against the pre-defined selection criteria. The application period for next year's EUPATI course will start in spring 2015.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.